Confirming ALK positivity in breast carcinoma, be it through molecular or immunohistochemical techniques, is important as it may become a contributor to clinical decision making, given the known therapeutic effect of ALK inhibitors in ALK-positive lung adenocarcinoma and neuroblastoma.[27,28] The relationship between ALK mutations or expression and breast carcinoma is however not fully understood, and various studies have shown different results, albeit with different methodologies. This evidence concerns the gene ALK and neuroblastoma.